AngioDynamics Inc., a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, has an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.
The transaction expands AngioDynamics’ growing oncology business by adding RadiaDyne’s early-stage, proprietary OARtrac, real-time radiation dose monitoring platform, and other market-leading oncology solutions, including the IsoLoc/ImmobiLoc and Alatus balloon stabilizing technologies.
“The acquisition of RadiaDyne, combined with our recent BioSentry asset purchase, delivers on our commitment to build a world-class oncology portfolio,” said Jim Clemmer, president and chief executive officer of AngioDynamics.